Jennifer Buol, LPN in Friend, NE - Licensed Vocational Nurse

Jennifer Buol, LPN is a Licensed Vocational Nurse based in Friend, Nebraska. Jennifer Buol is licensed to practice in Colorado (license number PN.0044039) and her current practice location is 501 S Main St, Friend, Nebraska. She can be reached at her office (for appointments etc.) via phone at (402) 947-2781.

NPI number for Jennifer Buol is 1750845194 and her current mailing address is 1201 Market St, Beatrice, Nebraska. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1750845194.

Contact Information

	Jennifer Buol, LPN
	501 S Main St, Friend, NE 68359-1349
	(402) 947-2781
	(402) 947-2951

Provider's Profile

Full Name	Jennifer Buol
Gender	Female
Speciality	Licensed Vocational Nurse
Location	501 S Main St, Friend, Nebraska
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1750845194
Provider Enumeration Date: 01/30/2019
Last Update Date: 01/30/2019

Medical Identifiers

Medical identifiers for Jennifer Buol such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1750845194	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
164X00000X	Licensed Vocational Nurse	PN.0044039 (Colorado)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Jennifer Buol is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Jennifer Buol, LPN 1201 Market St, Beatrice, NE 68310-4057 Ph: (402) 239-9436	Jennifer Buol, LPN 501 S Main St, Friend, NE 68359-1349 Ph: (402) 947-2781

News Archive

FDA disallows obesity drug Contrave pending further large-scale testing

In its latest blow to obesity medication development efforts, the US Food and Drug Administration (FDA) yesterday notified Orexigen Therapeutics that it would need to conduct an extremely large-scale study of the long-term cardiovascular effects of its drug, Contrave, before approval could be considered.

Third patient dosed in Phase 1/2 SMD trial using RPE cells derived from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today the dosing of third patient in its Phase 1/2 trial for Stargardt's macular dystrophy (SMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

Researchers show how antiretroviral therapy reduces HIV infection in female reproductive tract

For the first time, investigators in the Division of Infectious Diseases at the University of North Carolina School of Medicine have determined how antiretroviral therapy (ART) affects the way HIV disseminates and establishes infection in the female reproductive tract.

Merck's initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jennifer Buol, LPN - Licensed Vocational Nurse in Friend, NE